Senti Bio reports Q3 net loss of $16.6M; cash $114.9M; SENTI-202 and SENTI-301A IND filings on track for 2023

Senti Biosciences, Inc.

2022-Q3 EPS reported -$1.99 revenue$4,227,000

Net loss $16.6M ($0.38/share) for Q3 2022; R&D expenses $8.1M, G&A $10.8M.
Cash and equivalents $114.9M as of Sep 30, 2022; expected cash runway into 2024.
SENTI-202 IND on track for 2023; Phase 1 trial planned for CD33/FLT3+ hematologic malignancies including AML and MDS.
Selected SENTI-301A development candidate for GPC3+ solid tumors including HCC; IND expected in 2023.
Preclinical data for SENTI-301A and SENTI-401 presented at SITC; SENTI-202 data to be presented at ASH Dec 2022.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Senti Biosciences, Inc. reported financial results for the quarter ended September 30, 2022.

Period: the quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 10, 2022, Senti Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Senti Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001854270-22-000041

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.